Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anal Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Anal Cancer - Pipeline Review, H1 2015', provides an overview of the Anal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Anal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Anal Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Anal Cancer - Overview 7 Pipeline Products for Anal Cancer - Comparative Analysis 8 Anal Cancer - Therapeutics under Development by Companies 9 Anal Cancer - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Anal Cancer - Products under Development by Companies 12 Anal Cancer - Companies Involved in Therapeutics Development 13 Advaxis, Inc. 13 Amgen Inc. 14 Eli Lilly and Company 15 ISA Pharmaceuticals B.V. 16 MedImmune, LLC 17 Theravectys S.A. 18 Anal Cancer - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Combination Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 ADXS-HPV - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 durvalumab + tremelimumab - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ISA-101 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 LY-2606368 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 panitumumab - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Vaccine for HPV Associated Cancers - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Anal Cancer - Recent Pipeline Updates 40 Anal Cancer - Dormant Projects 51 Anal Cancer - Product Development Milestones 52 Featured News & Press Releases 52 Oct 15, 2014: Advaxis Provides Clinical Update for Phase 1/2 Trial of ADXS-HPV Immunotherapy Product Candidate in Anal Cancer 52 Feb 11, 2014: SynCo Bio Partners Expands Live Microbial Product Experience 52 Jun 24, 2013: Advaxis Requests Orphan Drug Designation For Treatment Of HPV-Associated Anal Cancer with ADXS-HPV 53 Apr 22, 2013: Advaxis Announces First Patient Dosed In Brown University Sponsored Phase I/II Anal Cancer Study Of ADXS-HPV 53 Mar 03, 2013: Advaxis Provides Update On ADXS-HPV Cancer Immunotherapy 54 Feb 19, 2013: Advaxis Announces Brown University Oncology Group To Conduct Phase I/II Trial Of ADXS-HPV In Anal Cancer 55 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 57 Disclaimer 58
List of Tables Number of Products under Development for Anal Cancer, H1 2015 7 Number of Products under Development for Anal Cancer - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Anal Cancer - Pipeline by Advaxis, Inc., H1 2015 13 Anal Cancer - Pipeline by Amgen Inc., H1 2015 14 Anal Cancer - Pipeline by Eli Lilly and Company, H1 2015 15 Anal Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2015 16 Anal Cancer - Pipeline by MedImmune, LLC, H1 2015 17 Anal Cancer - Pipeline by Theravectys S.A., H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Assessment by Combination Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 28 Anal Cancer Therapeutics - Recent Pipeline Updates, H1 2015 40 Anal Cancer - Dormant Projects, H1 2015 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.